Clinical and pharmacokinetic study of gemcitabine (GEM) - oxaliplatin (OXA) association in metastatic or locally advanced pancreatic adenocarcinoma.

被引：0
|
作者：
Airoldi, M
Cattel, L
Passera, R
Micari, C
Ferrarato, E
Zanon, C
机构：
[1] Osped San Giovanni Ant Sede, Turin, Italy
[2] Univ Turin, Fac Farm, Turin, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2059
引用
收藏
页码：141S / 141S
页数：1
相关论文
共 50 条
  • [21] CLINICAL TRIAL SIMULATIONS BASED ON A META-ANALYSIS OF STUDIES IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC ADENOCARCINOMA PANCREATIC CANCER RECEIVING GEMCITABINE (GEM) ALONE OR IN COMBINATION
    Bennetts, M.
    Nickens, D. J.
    Thurm, H. C.
    Hernandez, C. J.
    Ahadieh, S.
    Amantea, M. A.
    VALUE IN HEALTH, 2017, 20 (09) : A416 - A416
  • [22] FOLFIRINOX FOR LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA. RESULTS OF AN AGEO MULTICENTRIC PROSPECTIVE STUDY
    Marthey, L.
    Sa-Cunha, A.
    Blanc, J. F.
    Cueff, A.
    Francois, E.
    Trouilloud, I.
    Malka, D.
    Bachet, J.
    Coriat, R.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 238 - 238
  • [23] Gemcitabine plus oxaliplatin in advanced or metastatic pretreated pancreatic cancer
    Anghel, Rodica M.
    Popescu, Irinel
    Ionescu, Mihnea
    Stanculeanu, Dana
    Minea, Laurentia
    Bacinschi, Xenia
    Cringeanu, Alexandrina
    ANNALS OF ONCOLOGY, 2006, 17 : 325 - 325
  • [24] A phase I open-label dose-escalation study of AL2846 in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
    Liu, Rui
    Deng, Ting
    Bai, Ming
    Zhang, Le
    Ning, Tao
    Wang, Xia
    Ji, Zhi
    Yang, Yuchong
    Ge, Shaohua
    Li, Hongli
    Duan, Jingjing
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Clinical and molecular profiling of locally advanced compared with metastatic pancreatic adenocarcinoma
    Picardo, Sarah Louise
    O'Kane, Grainne M.
    Fischer, Sandra
    Zhang, Amy
    Denroche, Robert Edward
    Jang, Gun Ho
    Dodd, Anna
    Grant, Robert C.
    Grunwald, Barbara
    Moura, Shari
    Elimova, Elena
    Prince, Rebecca M.
    Zogopoulos, George
    Notta, Faiyaz
    Wilson, Julie
    Gallinger, Steven
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [26] Retrospective trial of concurrent gemcitabine (GEM) or infusional 5-fluoruracil (5-FU), folinic acid (FA), interferon (IFN) treatment in patients with locally advanced or metastatic pancreatic adenocarcinoma.
    Eickhoff, AS
    Jakobs, R
    Riemann, JF
    GASTROENTEROLOGY, 2000, 118 (04) : A517 - A517
  • [27] Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma
    Bullock, Andrea
    Stuart, Keith
    Jacobus, Susanna
    Abrams, Thomas
    Wadlow, Raymond
    Goldstein, Michael
    Miksad, Rebecca
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (06) : 945 - +
  • [28] A triple approach strategy for patients with locally advanced pancreatic adenocarcinoma.
    Cantore, M.
    Girelli, R.
    Mambrini, A.
    Frigerio, I.
    Boz, G.
    Simoncini, E.
    Lusenti, A.
    Orlandi, M.
    Bassi, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients (pts) with gemcitabine-refractory advanced pancreatic adenocarcinoma (PC)
    Starling, N.
    Hawkes, E. A.
    Chau, I.
    Watkins, D. J.
    Thomas, J.
    Webb, J.
    Brown, G.
    Thomas, K.
    Oates, J. R.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] A phase I trial of chemoradiation therapy with concurrent full dose gemcitabine for unresectable locally advanced pancreatic adenocarcinoma.
    Ioka, T
    Tanaka, S
    Nakaizumi, A
    Nishiyama, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 360S - 360S
12345